A citation-based method for searching scientific literature

F Stephen Hodi, Steven J O'Day, David F McDermott, Robert W Weber, Jeffrey A Sosman, John B Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C Hassel, Wallace Akerley, Alfons J M van den Eertwegh, Jose Lutzky, Paul Lorigan, Julia M Vaubel, Gerald P Linette, David Hogg, Christian H Ottensmeier, Celeste Lebbé, Christian Peschel, Ian Quirt, Joseph I Clark, Jedd D Wolchok, Jeffrey S Weber, Jason Tian, Michael J Yellin, Geoffrey M Nichol, Axel Hoos, Walter J Urba. N Engl J Med 2010
Times Cited: 10046







List of co-cited articles
863 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma.
Matthew J Frank, Patrick M Reagan, Nancy L Bartlett, Leo I Gordon, Jonathan W Friedberg, Debra K Czerwinski, Steven R Long, Richard T Hoppe, Robert Janssen, Albert F Candia,[...]. Cancer Discov 2018
90
3

Inflammatory microenvironment remodelling by tumour cells after radiotherapy.
Martin McLaughlin, Emmanuel C Patin, Malin Pedersen, Anna Wilkins, Magnus T Dillon, Alan A Melcher, Kevin J Harrington. Nat Rev Cancer 2020
176
3

The Tumor Microenvironment Innately Modulates Cancer Progression.
Dominique C Hinshaw, Lalita A Shevde. Cancer Res 2019
721
3

Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells.
Robert H Vonderheide, Patricia M LoRusso, Magi Khalil, Elaina M Gartner, Divis Khaira, Denis Soulieres, Prudence Dorazio, Jennifer A Trosko, Jens Rüter, Gabriella L Mariani,[...]. Clin Cancer Res 2010
208
2





Anti-HER2 vaccines: new prospects for breast cancer therapy.
Maha Zohra Ladjemi, William Jacot, Thierry Chardès, André Pèlegrin, Isabelle Navarro-Teulon. Cancer Immunol Immunother 2010
96
2

Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial.
Elizabeth A Mittendorf, Biao Lu, Michelle Melisko, Julie Price Hiller, Igor Bondarenko, Adrian Murray Brunt, Grybach Sergii, Katarina Petrakova, George E Peoples. Clin Cancer Res 2019
69
2

The interaction properties of costimulatory molecules revisited.
Alison V Collins, Douglas W Brodie, Robert J C Gilbert, Andrea Iaboni, Raquel Manso-Sancho, Björn Walse, David I Stuart, P Anton van der Merwe, Simon J Davis. Immunity 2002
452
2

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
2

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
Luc Y Dirix, Istvan Takacs, Guy Jerusalem, Petros Nikolinakos, Hendrik-Tobias Arkenau, Andres Forero-Torres, Ralph Boccia, Marc E Lippman, Robert Somer, Martin Smakal,[...]. Breast Cancer Res Treat 2018
367
2


Turning the corner on therapeutic cancer vaccines.
Robert E Hollingsworth, Kathrin Jansen. NPJ Vaccines 2019
283
2

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.
James L Gulley, Philip M Arlen, Ravi A Madan, Kwong-Yok Tsang, Mary P Pazdur, Lisa Skarupa, Jacquin L Jones, Diane J Poole, Jack P Higgins, James W Hodge,[...]. Cancer Immunol Immunother 2010
215
2



Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC.
Paul C Tumeh, Matthew D Hellmann, Omid Hamid, Katy K Tsai, Kimberly L Loo, Matthew A Gubens, Michael Rosenblum, Christina L Harview, Janis M Taube, Nathan Handley,[...]. Cancer Immunol Res 2017
265
2

A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151).
Lu Si, Xiaoshi Zhang, Yongqian Shu, Hongming Pan, Di Wu, Jiwei Liu, Fang Lou, Lili Mao, Xuan Wang, Xizhi Wen,[...]. Transl Oncol 2019
53
3

Dacarbazine in melanoma: from a chemotherapeutic drug to an immunomodulating agent.
Selma Ugurel, Annette Paschen, Jürgen C Becker. J Invest Dermatol 2013
26
7

Chemotherapeutic Treatments Increase PD-L1 Expression in Esophageal Squamous Cell Carcinoma through EGFR/ERK Activation.
Hoi Yan Ng, Jian Li, Lihua Tao, Alfred King-Yin Lam, Kwok Wah Chan, Josephine Mun Yee Ko, Valen Zhuoyou Yu, Michael Wong, Benjamin Li, Maria Li Lung. Transl Oncol 2018
55
3

Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial.
Bixia Tang, Zhihong Chi, Yingbo Chen, Xiufeng Liu, Di Wu, Jing Chen, Xin Song, Weifeng Wang, Lihou Dong, Haifeng Song,[...]. Clin Cancer Res 2020
50
4

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
Ajay V Maker, Giao Q Phan, Peter Attia, James C Yang, Richard M Sherry, Suzanne L Topalian, Udai S Kammula, Richard E Royal, Leah R Haworth, Catherine Levy,[...]. Ann Surg Oncol 2005
385
2

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma.
Caroline Robert, Wen-Jen Hwu, Omid Hamid, Antoni Ribas, Jeffrey S Weber, Adil I Daud, F Stephen Hodi, Jedd D Wolchok, Tara C Mitchell, Peter Hersey,[...]. Eur J Cancer 2021
24
8


CTLA4 blockade broadens the peripheral T-cell receptor repertoire.
Lidia Robert, Jennifer Tsoi, Xiaoyan Wang, Ryan Emerson, Blanca Homet, Thinle Chodon, Stephen Mok, Rong Rong Huang, Alistair J Cochran, Begoña Comin-Anduix,[...]. Clin Cancer Res 2014
237
2

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.
Celeste Lebbé, Nicolas Meyer, Laurent Mortier, Ivan Marquez-Rodas, Caroline Robert, Piotr Rutkowski, Alexander M Menzies, Thomas Eigentler, Paolo A Ascierto, Michael Smylie,[...]. J Clin Oncol 2019
154
2

Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors.
Chiaki Kurimoto, Hidefumi Inaba, Hiroyuki Ariyasu, Hiroshi Iwakura, Yoko Ueda, Shinsuke Uraki, Ken Takeshima, Yasushi Furukawa, Shuhei Morita, Yuki Yamamoto,[...]. Cancer Sci 2020
41
4


Management of immune-related adverse events and kinetics of response with ipilimumab.
Jeffrey S Weber, Katharina C Kähler, Axel Hauschild. J Clin Oncol 2012
2

CTLA-4 is a second receptor for the B cell activation antigen B7.
P S Linsley, W Brady, M Urnes, L S Grosmaire, N K Damle, J A Ledbetter. J Exp Med 1991
2

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).
Adi Diab, Nizar M Tannir, Salah-Eddine Bentebibel, Patrick Hwu, Vassiliki Papadimitrakopoulou, Cara Haymaker, Harriet M Kluger, Scott N Gettinger, Mario Sznol, Scott S Tykodi,[...]. Cancer Discov 2020
110
2

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.
Celine Boutros, Ahmad Tarhini, Emilie Routier, Olivier Lambotte, Francois Leroy Ladurie, Franck Carbonnel, Hassane Izzeddine, Aurelien Marabelle, Stephane Champiat, Armandine Berdelou,[...]. Nat Rev Clin Oncol 2016
577
2

Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature.
Houssein Safa, Daniel H Johnson, Van Anh Trinh, Theresa E Rodgers, Heather Lin, Maria E Suarez-Almazor, Faisal Fa'ak, Chantal Saberian, Cassian Yee, Michael A Davies,[...]. J Immunother Cancer 2019
86
2

B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression.
Jun Konishi, Koichi Yamazaki, Miyuki Azuma, Ichiro Kinoshita, Hirotoshi Dosaka-Akita, Masaharu Nishimura. Clin Cancer Res 2004
560
2

Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis.
Alexander Faje, Kerry Reynolds, Leyre Zubiri, Donald Lawrence, Justine V Cohen, Ryan J Sullivan, Lisa Nachtigall, Nicholas Tritos. Eur J Endocrinol 2019
61
3

Tertiary lymphoid structures improve immunotherapy and survival in melanoma.
Rita Cabrita, Martin Lauss, Adriana Sanna, Marco Donia, Mathilde Skaarup Larsen, Shamik Mitra, Iva Johansson, Bengt Phung, Katja Harbst, Johan Vallon-Christersson,[...]. Nature 2020
602
2

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
Caroline Robert, Antoni Ribas, Jedd D Wolchok, F Stephen Hodi, Omid Hamid, Richard Kefford, Jeffrey S Weber, Anthony M Joshua, Wen-Jen Hwu, Tara C Gangadhar,[...]. Lancet 2014
2


Phase I/II study of ipilimumab for patients with metastatic melanoma.
Jeffrey S Weber, Steven O'Day, Walter Urba, John Powderly, Geoff Nichol, Michael Yellin, Jolie Snively, Evan Hersh. J Clin Oncol 2008
351
2

B cells are associated with survival and immunotherapy response in sarcoma.
Florent Petitprez, Aurélien de Reyniès, Emily Z Keung, Tom Wei-Wu Chen, Cheng-Ming Sun, Julien Calderaro, Yung-Ming Jeng, Li-Ping Hsiao, Laetitia Lacroix, Antoine Bougoüin,[...]. Nature 2020
628
2

Ipilimumab-associated Hepatitis: Clinicopathologic Characterization in a Series of 11 Cases.
Melanie Johncilla, Joseph Misdraji, Daniel S Pratt, Agoston T Agoston, Gregory Y Lauwers, Amitabh Srivastava, Leona A Doyle. Am J Surg Pathol 2015
130
2

A new member of the immunoglobulin superfamily--CTLA-4.
J F Brunet, F Denizot, M F Luciani, M Roux-Dosseto, M Suzan, M G Mattei, P Golstein. Nature 1987
874
2

Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients.
Edward Cha, Mark Klinger, Yafei Hou, Craig Cummings, Antoni Ribas, Malek Faham, Lawrence Fong. Sci Transl Med 2014
281
2

Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade.
Feng Wang, Qian Yin, Liang Chen, Mark M Davis. Proc Natl Acad Sci U S A 2018
85
2

Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency.
Seiichi Yano, Kenji Ashida, Ryuichi Sakamoto, Chihiro Sakaguchi, Masatoshi Ogata, Kengo Maruyama, Shohei Sakamoto, Munehiko Ikeda, Kenji Ohe, Shoko Akasu,[...]. Eur J Cancer 2020
32
6

Management of Immunotherapy-Related Toxicities, Version 1.2019.
John A Thompson, Bryan J Schneider, Julie Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E Budde, Luciano Costa, Marianne Davies, David Dunnington,[...]. J Natl Compr Canc Netw 2019
254
2

Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies.
M Lisa Zhang, Azfar Neyaz, Deepa Patil, Jonathan Chen, Michael Dougan, Vikram Deshpande. Histopathology 2020
46
4

Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors.
Emma C de Moel, Elisa A Rozeman, Ellen H Kapiteijn, Els M E Verdegaal, Annette Grummels, Jaap A Bakker, Tom W J Huizinga, John B Haanen, René E M Toes, Diane van der Woude. Cancer Immunol Res 2019
66
3


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.